In 2013, there were an estimated 240,372 men living with testis cancer in the United States. The earlier testis cancer is caught, the better chance a person has of surviving five years after being diagnosed. 67.8% are diagnosed at the local stage and the 5-year survival for localized testis cancer is 99.3%. The number of testis cancer deaths is highest among men aged 20-34. Death rates have been stable over 2004-2013. (1)
The prognosis depends on the histology, extent of the disease, localization of metastases, tumor size and level of tumor markers. Patients with extragonadal nonseminoma with mediastinal localization fall into a poor prognostic group. Relapse after previous chemotherapy generally has a poor prognosis. About 25% of the patients live for 5 years. (2)
Five percent of patients with testicular cancer will develop new cancer in the contralateral testicle in their lifetime. (4)
All patients with metastasizing seminoma have either a good or intermediate prognosis. Seminoma in the good prognosis group has a 5-year survival of 86%, while the intermediary prognosis group has a 72% survival. (7)
Nonseminoma in the good prognostic group has a 5-year survival of 92%. In the intermediary prognostic group, 5-year survival is 80%. The poor prognostic group has a 48% of 5-year survival. (8)
Five-year relative survival of patients with testicular cancer, in percent, according to stage during the diagnosis period 1974–2013.
Source: Cancer Registry of Norway